chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.esmo.org/content/download/117241/2057634/file/esmo-2017-abstract-book.pdf

Outcomes of Prechemotherapy (preCRx) Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after ADT + Docetaxel (D) or ADT Alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in a Multi-Institution Hospital-based Registry / Francini Edoardo. - In: ANNALS OF ONCOLOGY. - ISSN 1569-8041. - ELETTRONICO. - (2017), pp. 0-0.

Outcomes of Prechemotherapy (preCRx) Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after ADT + Docetaxel (D) or ADT Alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in a Multi-Institution Hospital-based Registry.

Francini Edoardo
Writing – Original Draft Preparation
2017

Abstract

chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.esmo.org/content/download/117241/2057634/file/esmo-2017-abstract-book.pdf
2017
Francini Edoardo
1c - Abstract su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1341891
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact